Attaining precision therapy in prostate cancer: A tall order

Affiliations

Editorial

Eleni Efstathiou. Eur J Cancer. 2017 Aug.

. 2017 Aug:81:226-227.

doi: 10.1016/j.ejca.2017.05.011. Epub 2017 Jun 16.

¹ The University of Texas MD Anderson Cancer Center, Dept of Genitourinary Medical Oncology, USA. Electronic address: eefstathiou@mdanderson.org.

No abstract available

Comment on

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K. Massard C, et al. Eur J Cancer. 2017 May;76:36-44. doi: 10.1016/j.ejca.2017.01.024. Epub 2017 Mar 20. Eur J Cancer. 2017. PMID: 28282611 Clinical Trial.
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, Yu EY, George DJ. Armstrong AJ, et al. Eur J Cancer. 2017 Aug;81:228-236. doi: 10.1016/j.ejca.2017.02.030. Epub 2017 May 11. Eur J Cancer. 2017. PMID: 28502694 Free PMC article. Clinical Trial.

1. Bastos DA, Antonarakis ES. Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Des Devel Ther. 2016 Jul 15;10:2289–97. doi: 10.2147/DDDT.S93941. eCollection 2016. - DOI - PMC - PubMed
1. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424–33. doi: 10.1056/NEJMoa1405095. - DOI - PMC - PubMed
1. Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol. 2017 Jan;35(1):40–47. Epub 2016 Oct 31. - PubMed
1. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–86. - PMC - PubMed
1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376:1147–54. - PubMed